Adlai Nortye (NASDAQ:ANL) CFO Sells $83,880.00 in Stock

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) CFO Xiaofeng Ye sold 6,000 shares of the business’s stock in a transaction on Monday, August 24th. The stock was sold at an average price of $13.98, for a total transaction of $83,880.00. Following the transaction, the chief financial officer owned 153,424 shares in the company, valued at approximately $2,144,867.52. The trade was a 3.76% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Xiaofeng Ye also recently made the following trade(s):

• On Wednesday, August 26th, Xiaofeng Ye sold 5,667 shares of Adlai Nortye stock. The shares were sold at an average price of $14.25, for a total transaction of $80,754.75.

Adlai Nortye Trading Down 3.5%

Shares of ANL stock opened at $13.82 on Friday. The company has a fifty day moving average price of $12.16 and a two-hundred day moving average price of $11.21. Adlai Nortye Ltd. Sponsored ADR has a one year low of $0.88 and a one year high of $17.25. The company has a current ratio of 9.55, a quick ratio of 0.65 and a debt-to-equity ratio of 0.04.

Analyst Ratings Changes

A number of brokerages have weighed in on ANL. Cantor Fitzgerald started coverage on Adlai Nortye in a research report on Monday, June 22nd. They set an “overweight” rating on the stock. Wall Street Zen raised Adlai Nortye from a “hold” rating to a “buy” rating in a research report on Saturday, August 22nd. JonesTrading began coverage on Adlai Nortye in a research note on Thursday, May 14th. They set a “buy” rating and a $22.00 target price for the company. Weiss Ratings reissued a “sell (e+)” rating on shares of Adlai Nortye in a report on Tuesday, July 14th. Finally, Oppenheimer initiated coverage on Adlai Nortye in a report on Thursday, May 28th. They set an “outperform” rating and a $32.00 target price on the stock. Five analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $24.25.

Institutional Trading of Adlai Nortye

Institutional investors have recently modified their holdings of the stock. SmartHarvest Portfolios LLC raised its stake in Adlai Nortye by 8.5% in the first quarter. SmartHarvest Portfolios LLC now owns 16,367 shares of the company’s stock valued at $113,000 after purchasing an additional 1,279 shares in the last quarter. Renaissance Technologies LLC acquired a new stake in Adlai Nortye during the first quarter worth about $457,000. Affinity Asset Advisors LLC acquired a new stake in Adlai Nortye during the first quarter worth about $1,140,000. ADAR1 Capital Management LLC bought a new position in Adlai Nortye in the 1st quarter valued at about $816,000. Finally, Boone Capital Management LLC bought a new position in Adlai Nortye in the 2nd quarter valued at about $2,971,000. 35.21% of the stock is currently owned by institutional investors.

About Adlai Nortye

Adlai Nortye Inc (NASDAQ: ANL) is a specialty chemical manufacturer headquartered in China’s Jiangsu Province. The company focuses on the research, development, production and sale of fine chemicals, with a primary emphasis on amino acids and their derivatives.

Adlai Nortye’s product portfolio includes betaine compounds, a range of high-purity L-amino acids such as L-methionine, L-threonine and glycine, as well as various chemical intermediates. These offerings serve multiple end markets, including animal feed and nutrition, personal care and cosmetic formulations, pharmaceutical ingredients and industrial chemical processes.

The company operates multiple production facilities alongside an in-house research and development center dedicated to process innovation and quality control.